What happened
A study published online in JAMA on November 13 examined a fragment of the tau protein called eMTBR-tau243 in blood and cerebrospinal fluid. The investigators analyzed 229 participants across groups with Alzheimer disease and other tau-related conditions, using autopsy findings or genetic information to anchor some diagnoses. In a small group of 11 people with autopsy-confirmed chronic traumatic encephalopathy, or CTE, the fragment was elevated in advanced disease compared with cognitively unimpaired controls. Independent reporting in The Guardian on November 14 described the finding and emphasized that the signal did not reliably identify early CTE. CTE has been associated with repeated head impacts, but a definitive diagnosis currently depends on examination of brain tissue after death.
Why it matters
Researchers have long sought a way to study CTE in living people, particularly to distinguish its biological changes from symptoms that can also occur in other neurological disorders. A measurable blood signal could eventually support research, selection of participants for clinical studies and assessment of how disease changes over time. This experiment offers a biological clue rather than a ready-made diagnostic test. The fragment also rises in Alzheimer disease and certain other conditions with mixed forms of tau pathology, so a positive result cannot be treated as proof of CTE. Moreover, the number of confirmed CTE cases studied was small, and participants with advanced disease are not representative of people with subtle symptoms or earlier exposure histories.
What to watch next
The next important test is replication in much larger and more diverse groups, including people with documented exposure histories and carefully characterized neurological symptoms. Researchers need to establish whether combining eMTBR-tau243 with other biomarkers, imaging and clinical information improves specificity. Longitudinal studies must determine whether levels change before advanced disease and whether the test can distinguish CTE from Alzheimer disease and other tauopathies. Until such evidence is available, the result should not be used to reassure, diagnose or classify individuals who have experienced repeated head impacts.